Within days of each other, two deals highlighted very different paths for public medtech companies.
On July 27, American Industrial Partners completed its $1.27 billion acquisition of Avanos Medical, taking the pain management and specialty nutrition company private. Two days later, MIMEDX announced an agreement to acquire Sanara MedTech for approximately $350 million, combining two public wound care businesses.
One was a private equity buyout. The other was consolidation between two smaller public companies. Together, they point to another development in medtech M&A: remaining independent may be getting harder to justify for companies caught between startup scale and large-cap status.
In May, we described the medtech M&A environment as active but not yet a boom. Since then, the pace tracked by Compass AI suggests more of the conditions for an acceleration are falling into place.
Between May 1 and July 30, Compass AI recorded 13 medtech M&A transactions. Among the disclosed deals were Roche’s $1.05 billion acquisition of PathAI, Medtronic’s $650 million SPR Therapeutics deal, MIMEDX’s approximately $350 million Sanara transaction, Resmed’s $340 million acquisition of Noctrix Health, Olympus’ $270 million BioProtect deal, Artivion’s $175 million Endospan acquisition, and Zimmer Biomet’s iovera° transaction at $70 million upfront.
Another six transactions were announced or completed without disclosed values. Include the Avanos take-private, and approximately $4 billion in medtech has changed hands or been committed in a single quarter.
But Avanos and Sanara are particularly revealing.
AIP agreed in April to acquire Avanos for $25.00 per share in cash, valuing the company at approximately $1.272 billion. The transaction closed July 27, taking Avanos private and ending its NYSE listing.
The Sanara transaction follows a different playbook. MIMEDX agreed to acquire Sanara for approximately $35.00 per share through a combination of cash and MIMEDX stock, representing a 46% premium to Sanara’s 30-day average. The approximately $350 million deal is built around scale, cost efficiencies, and a broader wound care and surgical portfolio. The combined business expects 2027 revenue comfortably above $400 million at a 20%-plus adjusted EBITDA margin.
The strategic tuck-in trend remains intact. Medtronic, Resmed, Roche, and Olympus continue acquiring commercial-stage assets that complement existing growth franchises. SPR Therapeutics strengthens Medtronic in pain management. Noctrix expands Resmed’s clinical sleep health portfolio. PathAI adds to Roche’s diagnostics capabilities.
What is changing is the tier below.
Smaller and mid-cap public medtech companies can occupy an uncomfortable middle ground: too large for the traditional tuck-in playbook, but too small to be a platform. Thin trading volumes, compressed valuations, and the expense of remaining public can make independence less attractive.
Avanos illustrates one exit. A financial buyer can take a public medtech private, work on the business outside the scrutiny of quarterly markets, and potentially pursue another exit later.
MIMEDX and Sanara illustrate another. Combining two companies in the same market can create greater scale, eliminate overlapping costs, and produce a larger, more liquid public company.
The result is a market being reshaped from both directions. Strategics continue shopping for growth assets, while private equity and consolidation could increasingly thin the ranks of public small-cap medtech.
Sub-scale public medtech companies in cash-generative categories such as wound care, ENT, urology, specialty nutrition, and bone healing are worth watching for additional take-private transactions or consolidation.
So are the strategic buyers. A major medtech acquiring an entire public mid-cap company, rather than a private startup, would signal that the current tuck-in cycle is broadening.
Finally, watch the premiums. Avanos went for a modest cash number and Sanara for a rich 46%. The spread between those two prices is the spread between "no other bidders" and "an auction," and it tells you how contested this middle really is.
We combine LSI proprietary intelligence with live Compass AI deal data to make falsifiable, time-bound calls. Here’s what Compass AI predicts:
Join the LSI Mailing List
Upcoming Events
17011 Beach Blvd, Suite 500
Huntington Beach, CA 92647
© 2026 Life Science Intelligence, Inc., All Rights Reserved. | Privacy Policy | Your Privacy Choices | Delete my Data